Endovia Health Sciences has secured FDA Investigational New Animal Drug (INAD) File No. 14145 for CannEpil®, advancing its development for managing cancer-related pain in companion animals. This milestone opens the regulatory process for an important new veterinary therapeutic option.

Key Highlights

  • Endovia Health Sciences, Inc. achieved FDA INAD File No. 14145, marking the start of the regulatory process for CannEpil®.
  • CannEpil® aims to address pain management in dogs with cancer, a significant unmet need in veterinary care.
  • The development effort is guided by a collaboration agreement with Lupvindol Biosciences Ltd. facilitating the regulatory journey.

This achievement initiates the formal regulatory process for CannEpil® as an investigational veterinary pharmaceutical aimed at managing cancer-related pain in companion animals. This milestone underscores the company's commitment to addressing a critical need in veterinary medicine, given the absence of FDA-approved therapies specifically for pain associated with cancer in dogs.

Milestone Achievement

The establishment of INAD File No. 14145 marks the first regulatory milestone for Endovia Health's CannEpil® program under its collaboration with Lupvindol Biosciences Ltd. Following this development, the company is positioned to begin interactions with the FDA's Center for Veterinary Medicine, paving the way for future regulatory submissions. This collaboration provides a structured framework for product development and regulatory engagement, important elements as the company progresses through the necessary stages required for eventual market approval. This first milestone may enhance Endovia's credibility with investors and Stakeholders in the veterinary sector.

Focus on Companion Animals

Endovia Health’s CannEpil® is focused on managing cancer-related pain, particularly in older dogs where cancer is the leading cause of death. As there are no specific FDA-approved treatments for this condition, the initiative represents an essential advancement in companion-animal care, providing veterinarians with a potentially effective therapeutic option. Veterinarians currently face limitations with off-label treatments, which can be associated with various adverse effects including sedation and toxicity.

This initiative not only taps into a critical veterinary need but also aligns with advancements in cannabinoid-based therapies to manage pain effectively. A successful CannEpil® rollout could position Endovia as a leader in veterinary pharmaceutical development.

Strategic Development

The commitment to utilizing these regulatory pathways demonstrates Endovia's strategic intention to efficiently navigate the complexities of Drug Development in the veterinary sector. The company believes that CannEpil® has the potential to Fill a substantial gap in the current veterinary treatment environment, addressing the pressing need for effective pain management in companion animals. The successful navigation of this regulatory process could greatly enhance Endovia's market position and future Revenue potential.

Future Outlook

As Endovia Health progresses through the regulatory environment, it anticipates ongoing updates regarding both regulatory and development milestones related to CannEpil®. This includes finalizing product development plans and advancing necessary studies to support regulatory approvals. The timeline for subsequent updates has not been specified, but the emphasis on structured regulatory engagement indicates that the company is actively pursuing a disciplined approach to its cannabis-based veterinary therapeutics.

Stakeholders are likely to monitor Endovia closely as it continues on this path toward innovative solutions in companion-animal health.